The U.S. FDA paused Moderna's norovirus vaccine trial due to a rare side effect. U.S. Health Secretary Robert F. Kennedy Jr's initiatives may face budget cuts. Wyoming reports a human bird flu case.

Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...

said the Drug Control Authority (DCA) agreed to give conditional approval to Spikevax, or what is commonly known as the Moderna Covid-19 vaccine.

Moderna stock has been under pressure ... Within respiratory vaccines, the company anticipates FDA approval for an expanded indication of its RSV vaccine. Furthermore, the company has submitted ...

Kennedy — a vaccine critic, obesity-drug skeptic and processed-foods hater — has secured ... Kennedy refused to say don't cause autism during his confirmation hearings. Moderna Inc.’s entire business ...

As Moderna (NASDAQ ... the biggest earning potential that could be approved are its combination shot for influenza and COVID, its influenza vaccine, and its next-generation COVID vaccine.

The World Health Organization wants to tackle inequity and bureaucracy relating to clinical trials. Will its latest guidance make a difference? Anna Volkmer reports During the covid-19 pandemic the UK ...

At the same time, Moderna’s partnership with Merck, developing mRNA-based Personalized Cancer Vaccines ("PCVs") for use in conjunction with KEYTRUDA, the world’s largest drug by revenue ...

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

Biotechnology company Moderna (NASDAQ:MRNA) gained the spotlight in the medical sector as a leader in the race toward a COVID-19 vaccine ... need (enabling quicker FDA approval).